Key result
Onasemnogene abeparvovec gene replacement therapy in 42 children with spinal muscular atrophy was associated with elevated troponin I in 26.2% (11/42), which was mostly asymptomatic.
Why the study?
Gene replacement therapy with onasemnogene abeparvovec for SMA may cause non-target cardiovascular changes requiring early diagnosis and monitoring.
Does gene replacement therapy with onasemnogene abeparvovec cause troponin I elevation and acute myocarditis in children with spinal muscular atrophy?
Observational (n=42)
Does gene replacement therapy with onasemnogene abeparvovec cause troponin I elevation and acute myocarditis in children with spinal muscular atrophy?
Troponin I elevations after onasemnogene abeparvovec therapy in SMA patients are common and often asymptomatic, but rare cases of acute myocarditis warrant prolonged cardiac monitoring.
Introduction. Spinal muscular atrophy (SMA) 5q is a rare genetically determined progressive neuromuscular disorder, is the most frequent cause of infant death not long ago. Nowadays onasemnogen abeparvovec as pathogenetic therapy is successfully used in clinical practice to combat this disease. Gene replacement therapy (GRT) with onasemnogen abeparvovec for SMA patients may come amid non-target changes in the cardiovascular system that require early diagnosis and monitoring. Objective. To present clinical reports considering children with genetically confirmed SMA and elevated troponin I levels after onasemnogen abeparvovec gene replacement therapy. Materials and methods. We monitored forty two children with genetically confirmed SMA who received gene replacement therapy with onasemnogen abeparvovec in the pediatric neurology department. All patients were tested for troponin I before and after the infusion, additional tests of N-Terminal Pro-B-Type Natriuretic Peptide (NT-proBNP), creatine phosphokinase-MB (CPK-MB), electrocardiogram, echocardiography were made if needed. Results. In 11 (26.2%) of 42 SMA children troponin I was elevated and detected up to the eighth week after drug administration. At the same time, an increased concentration of troponin I in the majority of cases (41 out of 42 children) was not associated with clinically significant manifestations. There was only one case when acute myocarditis, confirmed by clinical and instrumental methods of investigation occurred. It was a girl with a long-term (10 months) elevation of troponin I, who had an intercurrent infection. Conclusions. Troponin I elevations detected after GRT with onasomnogene abeparvovec in SMA patients are often asymptomatic. This myocarditis case highlights the importance of longer cardiac monitoring of troponin I elevations, especially in the presence of intercurrent bacterial and viral infections.
No takes yet. Share an insight, caveat, or question.
Papina et al. (2023) conducted an observational in Spinal muscular atrophy (SMA) (n=42). Onasemnogene abeparvovec was evaluated on Elevated troponin I levels. Onasemnogene abeparvovec gene replacement therapy in 42 children with spinal muscular atrophy was associated with elevated troponin I in 26.2% (11/42), which was mostly asymptomatic.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: